{"filings":[{"id":556760,"accession_number":"0001493152-26-024664","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2026-05-20T21:14:33+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChronoScale Amends Phantom PSU Awards for Three Executives After Change in Control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scott Davis's Phantom PSU amended to settle as 109,357 shares of common stock plus $1,000,000 cash.","Jerome Wong's Phantom PSU amended to settle entirely in 40,000 shares of common stock.","Jason Jones's Phantom PSU amended to settle entirely in 32,000 shares of common stock.","Amendments follow May 5, 2026 closing of Contribution and Exchange Agreement with Applied Digital Cloud Corp.","Phantom PSUs originally granted Nov 5, 2025 vested upon achieving Stock Price Goal and Change in Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93567,"accession_number":"0001493152-26-021330","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","2.01","2.02","3.02","3.03","4.01","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.","Company issued 138,216,820 new shares to Contributor for 100% of Cloud; post-merger shares outstanding 143,093,381.","Applied Parent invested $15.75M via PIPE at $12.01/share, receiving 1,311,407 shares.","Board reconstituted with 4 APLD designees (Wes Cummins as Chairman); ticker changes to 'CHRN' on Nasdaq.","Fiscal year end changed to May 31; authorized common shares increased to 290M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93568,"accession_number":"0001493152-26-021099","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Ekso Bionics to close business combination with Applied Digital, PIPE $15.75M, ticker becomes CHRN","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination with Applied Digital subsidiary closes May 5, 2026; company renames to ChronoScale Corporation.","Applied Digital (parent) buys 1,311,407 shares at $12.01/share in PIPE, gross proceeds ~$15.75M.","New ticker symbol 'CHRN' on Nasdaq; CUSIP changes to 170924104.","Lake Street Capital Markets serves as placement agent, receives 5% cash fee (~$0.75M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105299,"accession_number":"0001437749-26-004205","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","2.02","3.02","3.03","5.03","5.01","5.02","9.01"],"status":"ready","headline":"Ekso to merge with Applied Digital Cloud in reverse merger; APLD to own ~97%, rename to ChronoScale","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exchange: Ekso issues 138.2M shares to APLD for 100% of Cloud; APLD expects ~97% ownership of combined company.","Closing expected Q2 2026, subject to stockholder approval, SEC clearance, and minimum $15M cash condition including PIPE.","Preliminary Q4 2025 revenue $3.0-3.1M, down from $5.1M YoY; gross margin ~52-53%; cash $1.2M as of Dec 31, 2025.","Company used ~$4.3M net cash in operations in Q4 2025, vs $1.4M in Q4 2024; cash excludes Jan 2026 PIPE proceeds.","Board to be chaired by Wes Cummins (APLD); other initial APLD designees: Jason Zhang, Ella Benson, Richard Nottenburg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105298,"accession_number":"0001437749-26-001774","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Ekso Bionics raises ~$5.3M net via private placement of Series B convertible preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants for 355,960 shares.","Conversion price and warrant exercise price set at $8.22 per share of common stock; 6-month lock-up on transfers.","Net proceeds of ~$5.3M after ~$0.4M placement agent fees; intended for working capital and general corporate purposes.","Filed Certificate of Designation for Series B Preferred with Nevada Secretary of State on January 22, 2026.","Lake Street Capital Markets acted as exclusive placement agent; received a 6% cash fee and a warrant for 14,238 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121576,"accession_number":"0001437749-25-038864","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ekso Bionics and Applied Digital propose business combination; EKSO holders get ~3% of ChronoScale","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Applied Digital to spin out cloud business, combine with EKSO to form ChronoScale Corporation.","Upon closing, Applied Digital would own ~97% of combined company; EKSO existing stockholders ~3%.","EKSO plans to explore sale of all or substantially all of its current business.","Applied Digital Cloud generated ~$75.2M revenue in TTM ending Aug 31, 2025.","Proposed transaction expected to close in first half of 2026, subject to approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121575,"accession_number":"0001437749-25-033889","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ekso Bionics awards 114.5k RSUs and 257k phantom PSUs to Davis, Wong, Jones; new severance deals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Davis: 80k RSUs + 185k phantom PSUs; severance 9 months (non-CIC) or 18 months salary (CIC).","Jerome Wong: 19.5k RSUs + 40k phantom PSUs; severance 6 months (non-CIC) or 9 months salary (CIC).","Jason Jones: 15k RSUs + 32k phantom PSUs; severance 6 months (non-CIC) or 9 months salary (CIC).","Phantom PSUs vest only upon Change in Control and stock price ≥$7.50; settled in cash, not shares.","All RSU grants fully vested as of grant date; phantom PSUs have a 5-year performance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121574,"accession_number":"0001437749-25-032276","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Ekso Bionics raises $3.2M net in registered direct offering of 769,490 shares at $4.81","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 769,490 shares at $4.81 per share to institutional investors; net proceeds ~$3.2M.","Closing expected on or about October 30, 2025, subject to customary conditions.","Proceeds for general corporate purposes: R&D, SG&A, and working capital.","Issued placement agent warrant to Lake Street Capital Markets for 15,389 shares at $4.81.","Offering conducted under existing effective shelf registration statement (File No. 333-272607)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121573,"accession_number":"0001437749-25-031957","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q3 revenue $4.2M (+2% YoY); exploring sale or acquisition of different industry","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $4.2M, up 2% YoY and 105% sequentially; gross margin 60.3% vs 53.5% last year.","Net loss narrowed 31% YoY to $1.4M ($0.54/share) from $2.1M ($1.53/share).","Cash $2.7M as of Sept 30, 2025.","Company exploring strategic transactions including acquisition of a non-exoskeleton business or sale of substantially all assets.","Any transaction would require stockholder approval; no timetable set for strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138234,"accession_number":"0001437749-25-029285","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Ekso Bionics enters $2M secured loan with B. Riley at 10% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Agreement with B. Riley Commercial Capital for up to $2.0M secured term loan, maturing Sept 14, 2026 or upon qualified equity raise of $2.4M.","Interest at 10% per annum; exit fee of $200K (10% of principal) due at maturity.","Loan may convert into equity in connection with a qualified financing at the lead investor's price.","Existing $2.0M loan from Banc of California (Pacific Western Bank) terminated and fully paid off.","Proceeds for working capital and general corporate purposes; secured by substantially all personal property of company and subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138233,"accession_number":"0001437749-25-023643","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.","Gross margin 40% vs 53% prior year; gross profit $0.8M vs $2.6M.","Net loss $2.7M ($1.24/share) vs $2.4M ($1.99/share) in Q2 2024.","Personal Health device sales grew >50% YoY in H1 2025; cash $5.2M at June 30.","Named Bionic P&O as first Ekso Indego Personal distributor; joined NVIDIA Connect program."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":5432000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155684,"accession_number":"0001437749-25-018005","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ekso Bionics updates reverse stock split effective date to June 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 effective June 2, 2025; originally planned May 27.","Approved by shareholders on May 16; aims to regain Nasdaq $1.00 minimum bid price.","Pre-split shares ~35.5M; post-split ~2.4M outstanding; fractional shares rounded up.","Common stock to trade on Nasdaq under symbol EKSO on split-adjusted basis.","New CUSIP number 282644 400 will apply after the split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155683,"accession_number":"0001437749-25-017680","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Ekso Bionics approves 1-for-15 reverse stock split effective May 27, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-15; effective 12:01 a.m. PT on May 27, 2025.","Post-split shares ~2.35M vs pre-split ~35.3M; par value unchanged at $0.001.","Stock will trade on Nasdaq (symbol EKSO) on split-adjusted basis; new CUSIP 282644400.","Fractional shares rounded up to next whole share; no proportional cut in authorized shares.","Purpose: raise per-share price to meet $1 minimum bid for 10 consecutive trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155682,"accession_number":"0001437749-25-014527","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q1 2025 revenue $3.4M, net loss $2.9M; partnerships expand distribution","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $3.4M down 11% YoY ($3.8M); net loss $2.9M ($0.12/sh) vs $3.4M ($0.20/sh) in Q1 2024.","Gross margin improved to 53.5% from 51.9%; cash used in operations fell 43% to $2.0M.","Named National Seating & Mobility as exclusive U.S. CRT distributor for Ekso Indego Personal.","Appointed Bionic Prosthetics & Orthotics Group as first O&P distributor for Ekso Indego Personal.","Cash and restricted cash $8.1M at March 31, 2025; $3.8M net proceeds from warrant exercises."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":3375000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174169,"accession_number":"0001437749-25-007795","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Ekso Bionics raises $4.15M via warrant exercise; issues new 10.5M-share warrant at $0.4239","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing holder exercises 9.8M warrants for $4.15M at $0.4239/share; company receives cash proceeds.","Company issues new warrant for 10.5M shares at $0.4239/share, exercisable upon stockholder approval due by July 15, 2025.","Company agrees to share issuance standstill until May 31, 2025; no variable rate transactions until Sept 13, 2025.","New warrant has 4.99% beneficial ownership limit (holder may increase to 9.99% with 61 days' notice).","Company must file resale registration statement for new warrant shares within 30 days of stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174168,"accession_number":"0001437749-25-005911","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.","FY 2024 revenue $17.9M, down 2% YoY; net loss $11.3M ($0.56/sh), 25% better than FY 2023.","Cash and restricted cash $6.5M at Dec 31, 2024; operating cash burn improved to $9.8M from $12.1M.","Post-year-end, named National Seating & Mobility exclusive U.S. distributor for Ekso Indego Personal device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174167,"accession_number":"0001437749-25-000928","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).","Cash $6.5M at Dec 31, 2024, down from $8.6M a year earlier.","Net cash used in ops Q4 2024 estimated $1.5M, improving from $1.6M year ago.","CEO highlights initial CMS reimbursement for Ekso Indego Personal device.","Full Q4 and FY 2024 results expected in first week of March 2025."],"consensus_eps_estimate":-0.2907,"consensus_eps_actual":-8.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":17925000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191114,"accession_number":"0001437749-24-037475","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ekso Bionics receives Nasdaq bid price deficiency notice; has until June 10, 2025 to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice dated Dec 12, 2024: common stock bid price below $1.00 for 31 consecutive business days.","Company has 180 calendar days, until June 10, 2025, to regain compliance under Nasdaq Listing Rule 5810(c)(3)(A).","To regain compliance, closing bid price must be $1.00 or more for at least ten consecutive business days.","If not cured by June 10, 2025, Company may seek a second 180-day period if meeting all other initial listing standards and intends a reverse stock split.","Failure to regain compliance or secure extension could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191113,"accession_number":"0001437749-24-032290","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.","Gross margin improved to 53.5% from 53.3% on supply chain cost savings.","Net loss narrowed to $2.1M ($0.10/share) from $3.4M ($0.24/share) YoY.","Received CMS reimbursement for Ekso Indego Personal, enabling Medicare coverage for SCI patients.","Cash $8.3M at Sep 30, 2024; raised $5.0M net in underwritten offering during September."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":12835000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207583,"accession_number":"0001437749-24-028253","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ekso Bionics raises ~$5.1M net in underwritten public offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3.1M units at $1.00/unit (share + Series A/B warrants) and 2.9M pre-funded units at $0.9990/unit.","Net proceeds after underwriting discount and expenses were approximately $5.1 million.","Each Series A and B warrant exercisable at $1.00 per share; pre-funded warrants at $0.001.","Executive officers and directors subject to 90-day lock-up on common stock sales.","Underwriter is Craig-Hallum Capital Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207582,"accession_number":"0001437749-24-023753","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.","Net loss $2.4M ($0.13/sh) vs $4.2M ($0.31/sh) in Q2 2023, narrowing significantly.","Sold 37 EksoHealth devices in Q2; initial Medicare claims for Ekso Indego Personal pending.","Operating expenses decreased across all categories: SG&A down 21%, R&D down 20%, G&A down 28%.","Cash at June 30, 2024 $5.9M, down from $8.6M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":8706000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207581,"accession_number":"0001437749-24-023606","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K/A","filed_at":"2024-07-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ekso Bionics board elects annual say-on-pay vote after stockholder advisory frequency vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined on July 25, 2024 to hold future advisory votes on executive compensation annually.","Frequency matches board's proxy recommendation and stockholder vote at June 6, 2024 annual meeting.","Decision disclosed via 8-K/A amendment to report the frequency determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225029,"accession_number":"0001437749-24-019834","cik":1549084,"company_name":"EKSO BIONICS HOLDINGS, INC.","ticker":"CHRN","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ekso Bionics shareholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Scott Davis, Mary Ann Cloyd, Corinna Lathan, Charles Li, Deborah Lafer Scher.","Equity incentive plan extended to April 2034; authorized shares increased to 4,724,286 (1M increase).","Advisory say-on-pay approved: 6,303,399 for, 631,663 against, 124,065 abstained.","Annual frequency for future advisory votes selected: 6,840,255 for 1 year.","WithumSmith+Brown ratified as auditor for FY2024: 11,245,624 for, 153,991 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":52880576.036939315,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}